Colombus, OH - New research is increasingly drawing attention to the antiparasitic drug Ivermectin for its emerging role in cancer treatment. Long used for parasitic infections, Ivermectin is now being investigated for its anticancer properties following a wave of laboratory and early clinical studies indicating promising outcomes in various cancer types. These findings contribute to renewed scientific and public interest, positioning Ivermectin as a potential adjunctive therapy in oncology.
At the forefront of this movement is Dr. William Makis, a physician and researcher whose approach to integrative cancer care has brought renewed focus to the therapeutic potential of off-label medications. Dr. Makis has advocated for the use of both Ivermectin and Mebendazole, another antiparasitic agent, in cancer treatment. Through his innovative protocols, he has reported measurable success in patients for whom traditional treatment routes had limited efficacy. His work, highlighted by ongoing patient case reviews and clinical observations, reflects a broader shift toward exploring repurposed medications in modern cancer care.
Several peer-reviewed publications have added credibility to this movement, providing data that supports the antitumor effects of Ivermectin. These studies show that Ivermectin can interfere with key signaling pathways used by cancer cells, including inhibiting WNT-TCF, Akt/mTOR, and PAK1 signaling. Moreover, it has been observed to induce apoptosis, reduce cancer cell proliferation, and inhibit angiogenesis. A deeper look into these findings is available through recent studies on Ivermectin and cancer, which outline research from 2023 to 2024 across various cancer types, including breast, colorectal, and lung cancers.
FirstMed Inc, a global medical distributor, has responded to the growing interest in Ivermectin’s potential role in oncology by expanding its stock to meet increasing demand. With a central location in Ohio, the company is well-positioned to dispatch orders across the United States and Canada swiftly.
As awareness of the drug’s emerging use continues to rise, FirstMed Inc has also reported a significant uptick in inquiries and orders from Canadian practitioners and patients. Their domestic availability of Ivermectin ensures timely delivery for healthcare providers and individuals seeking alternative therapeutic approaches.
While Ivermectin and its many uses remain a subject of ongoing investigation, its international availability continues to expand. For example, in regions such as Australia, interest in over-the-counter access has risen as more individuals explore nontraditional treatment paths. An updated guide on the availability of Ivermectin in Australia outlines recent regulatory changes and access options for consumers and practitioners in that region.
As research continues and clinical evidence grows, the potential role of Ivermectin in cancer treatment may further solidify its place within the realm of adjunctive therapies, challenging long-standing conventions in cancer pharmacology.
About FirstMed Inc:
FirstMed Inc is a global medical supply and pharmaceutical distribution company with a warehouse in Ohio. The company provides high-quality medical products and medications, focusing on efficiency, accessibility, and innovation. With a rapidly expanding national network, FirstMed Inc has become a trusted resource for healthcare providers seeking timely access to specialized medications.
Media Contact
Name
FirstMed Inc
Contact name
Clint Dalby
City
Columbus
State
OH
Zip
43215
Country
United States
Url
https://firstmedinc.com/
